NASDAQ:IMMP Immutep (IMMP) Stock Price, News & Analysis $2.64 +0.01 (+0.38%) (As of 09/13/2024 ET) Add Compare Share Share Today's Range$2.61▼$2.6850-Day Range$1.77▼$2.6452-Week Range$1.58▼$3.34Volume88,940 shsAverage Volume248,520 shsMarket Capitalization$313.84 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immutep alerts: Email Address Immutep MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside203.0% Upside$8.00 Price TargetShort InterestBearish4.06% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.24) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.82 out of 5 starsMedical Sector813th out of 919 stocksPharmaceutical Preparations Industry378th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingImmutep has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmutep has only been the subject of 1 research reports in the past 90 days.Read more about Immutep's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.06% of the outstanding shares of Immutep have been sold short.Short Interest Ratio / Days to CoverImmutep has a short interest ratio ("days to cover") of 14.2, which indicates bearish sentiment.Change versus previous monthShort interest in Immutep has recently decreased by 2.23%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmutep does not currently pay a dividend.Dividend GrowthImmutep does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMMP. Previous Next 1.5 News and Social Media Coverage News SentimentImmutep has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Immutep this week, compared to 1 article on an average week.MarketBeat FollowsOnly 3 people have added Immutep to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immutep insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.07% of the stock of Immutep is held by insiders.Percentage Held by InstitutionsOnly 2.32% of the stock of Immutep is held by institutions.Read more about Immutep's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immutep are expected to decrease in the coming year, from ($0.24) to ($0.28) per share.Price to Book Value per Share RatioImmutep has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows this. That’s why in his recent interview with Trump, he brought up this technology as a viable solution to America’s growing energy needs. What is this technology and why has it put Elon in the middle of an ideological war with the elites?Watch my new exposé and find out. About Immutep Stock (NASDAQ:IMMP)Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Read More IMMP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMMP Stock News HeadlinesSeptember 8, 2024 | americanbankingnews.comFY2025 EPS Estimates for Immutep Limited (NASDAQ:IMMP) Raised by AnalystSeptember 7, 2024 | americanbankingnews.comCapital One Financial Comments on Immutep Limited's FY2029 Earnings (NASDAQ:IMMP)September 15, 2024 | Weiss Ratings (Ad)The #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”August 14, 2024 | finance.yahoo.comImmutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 AntibodyJuly 31, 2024 | globenewswire.comImmutep Quarterly Activities Report Q4 FY24July 11, 2024 | globenewswire.comImmutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 ExpressionJuly 3, 2024 | globenewswire.comImmutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical ResultsJune 25, 2024 | globenewswire.comImmutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for CancerSeptember 15, 2024 | Weiss Ratings (Ad)The #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”June 5, 2024 | globenewswire.comImmutep successfully completes institutional placement and institutional component of entitlement offerJune 2, 2024 | globenewswire.comImmutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III TrialMay 15, 2024 | globenewswire.comImmutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024May 2, 2024 | globenewswire.comPositive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue SarcomaMay 1, 2024 | seekingalpha.comImmutep: Realizing The Expected Catalysts, With More To ComeApril 29, 2024 | globenewswire.comImmutep Quarterly Activities Report Q3 FY24April 26, 2024 | markets.businessinsider.comImmutep’s Efti Shows Promise in Cancer Therapy, Analyst Maintains Buy RatingApril 25, 2024 | markets.businessinsider.comImmutep Buy Rating Justified by Strong Clinical Trial Results and Promising Future ProspectsApril 24, 2024 | markets.businessinsider.comImmutep Reports Positive Preliminary Topline Results From TACTI-003 Cohort BSee More Headlines Receive IMMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/15/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMMP CUSIPN/A CIK1506184 Webwww.immutep.com Phone(128) 315-7003Fax61-2-8569-1880Employees2,021Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+203.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio18.25 Quick RatioN/A Sales & Book Value Annual Sales$5.14 million Price / Sales61.06 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book2.51Miscellaneous Outstanding Shares118,880,000Free Float85,231,000Market Cap$313.84 million OptionableOptionable Beta2.20 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Marc Voigt (Age 51)CEO, MD, CFO, Chief Business Officer & Executive Director Comp: $378.64kMs. Deanne Miller LLB (Age 47)COO, General Counsel & Joint Company Secretary Comp: $247.61kDr. Frederic Triebel M.D. (Age 69)Ph.D., Chief Scientific Officer & Executive Director Comp: $302.26kMr. Christian Mueller BBAMSc., Senior Vice President of Regulatory & StrategyMr. Florian D. Vogl M.D.M.Sc., Ph.D., Chief Medical OfficerMs. Indira NaiduJoint Company SecretaryMore ExecutivesKey CompetitorsNurix TherapeuticsNASDAQ:NRIXRelay TherapeuticsNASDAQ:RLAYEvotecNASDAQ:EVOCalliditas Therapeutics AB (publ)NASDAQ:CALTTarsus PharmaceuticalsNASDAQ:TARSView All CompetitorsInstitutional OwnershipXTX Topco LtdBought 12,958 shares on 8/12/2024Ownership: 0.015%XY Capital LtdBought 52,005 shares on 8/5/2024Ownership: 0.044%View All Institutional Transactions IMMP Stock Analysis - Frequently Asked Questions How have IMMP shares performed this year? Immutep's stock was trading at $2.40 at the start of the year. Since then, IMMP stock has increased by 10.0% and is now trading at $2.64. View the best growth stocks for 2024 here. Who are Immutep's major shareholders? Top institutional investors of Immutep include XY Capital Ltd (0.04%) and XTX Topco Ltd (0.01%). How do I buy shares of Immutep? Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Immutep own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD) and Heat Biologics (HTBX). This page (NASDAQ:IMMP) was last updated on 9/15/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMMP Stock Alerts